MedTrace Logo

Effectiveness of a Typhoid Conjugate Vaccine in DRC

NCT05119426 · Status: UNKNOWN · Phase: PHASE4 · Type: INTERVENTIONAL · Enrollment: 48000

Last updated 2023-04-18

No results posted yet for this study

Summary

This is a prospective cohort evaluation of vaccine effectiveness of a single dose of Typbar-TCV® against symptomatic blood culture-confirmed typhoid fever when administered through a mass vaccination campaign to children 9 months to \<16 years of age in Kisantu, DRC.

Conditions

  • Typhoid Fever

Interventions

BIOLOGICAL

Vi-TT

Single dose of vaccine administered through a mass vaccine campaign to children between 9 months and \<16 years of age. The campaign will emulate vaccine delivery as would be administered in a local mass vaccination campaign.

Sponsors & Collaborators

  • Institut National de Recherche Biomédicale. Kinshasa, République Démocratique du Congo

    collaborator OTHER

  • University of Cambridge

    collaborator OTHER

  • Institute of Tropical Medicine, Belgium

    collaborator OTHER

  • International Vaccine Institute

    lead OTHER

Principal Investigators

  • Florian Marks, PhD · University of Cambridge

  • Octavie Lunguya, PhD · Institut National de Research Biomédicale

Study Design

Allocation
NA
Purpose
PREVENTION
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
9 Months
Max Age
15 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2022-02-11
Primary Completion
2024-12-31
Completion
2024-12-31

Countries

  • Democratic Republic of the Congo

Study Locations

More Related Trials

Entities

Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05119426 on ClinicalTrials.gov